- Home
- Equipment
- north america
- drug conjugation
Show results for
Refine by
Drug Conjugation Equipment Supplied In North America
54 equipment items found
by:Sword Diagnostics, Inc. based inCarmel, INDIANA (USA)
Sword scientists will use our cell-based assay development expertise to develop a customized method to corroborate the binding specificity of your antibody-drug conjugate (ADC). Our understanding of the molecular basis of cellular growth, proliferation, and differentiation is continually evolving as the genes, proteins, and biochemical pathways critical to these ...
by:DEARGEN Inc. based inDaejeon, SOUTH KOREA
ADC (Antibody-drug conjugate) is a next-generation antibody-drug conjugate that has improved efficacy over existing antibodies. This drug combines the advantages of two factors: target specificity, which is a characteristic of an antibody, and cytotoxicity, which is a characteristic of a drug. ...
by:Sutro Biopharma Inc. based inSouth San Francisco, CALIFORNIA (USA)
Sutro’s cell-free expression technology provides a rapid and powerful platform for the discovery and development of next generation antibody-drug conjugates ...
by:Zymeworks Inc based inVancouver, BRITISH COLUMBIA (CANADA)
ZW49 is a HER2-targeted antibody drug conjugate (ADC) developed using Zymeworks’ proprietary Azymetric™ and ZymeLink™ platforms. ZW49 is currently being evaluated in a Phase 1 clinical trial as a treatment for patients with locally advanced or metastatic HER2-expressing cancers that have progressed following treatment with existing approved ...
Manufactured by:SystImmune Inc. based inRedmond, WASHINGTON (USA)
Antibody Drug Conjugates (ADC) molecules utilize specific antibodies to deliver therapeutic small molecules specifically to cancer cells. ADC are created in cooperation with Bai-Li Pharmaceutical’s R&D Center of Excellence and enable the development of sophisticated chemistries that give this class of drugs their therapeutic ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
CytomX is developing CX-2009, a Probody drug conjugate (PDC) conjugated with DM4, a highly potent cytotoxic drug, targeting CD166, also known as ALCAM. CD166 is a molecule widely and highly expressed on solid tumor cells and previously considered “undruggable” given its expression on normal tissues. In preclinical ...
Manufactured by:SystImmune Inc. based inRedmond, WASHINGTON (USA)
Antibody Drug Conjugates (ADC) molecules utilize specific antibodies to deliver therapeutic small molecules specifically to cancer cells. ADC are created in cooperation with Bai-Li Pharmaceutical’s R&D Center of Excellence and enable the development of sophisticated chemistries that give this class of drugs their therapeutic ...
Manufactured by:SystImmune Inc. based inRedmond, WASHINGTON (USA)
Antibody Drug Conjugates (ADC) molecules utilize specific antibodies to deliver therapeutic small molecules specifically to cancer cells. ADC are created in cooperation with Bai-Li Pharmaceutical’s R&D Center of Excellence and enable the development of sophisticated chemistries that give this class of drugs their therapeutic ...
Manufactured by:SystImmune Inc. based inRedmond, WASHINGTON (USA)
Antibody Drug Conjugates (ADC) molecules utilize specific antibodies to deliver therapeutic small molecules specifically to cancer cells. ADC are created in cooperation with Bai-Li Pharmaceutical’s R&D Center of Excellence and enable the development of sophisticated chemistries that give this class of drugs their therapeutic payload. ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
CytomX and AbbVie are co-developing CX-2029, a PDC directed against CD71, the transferrin receptor that is highly expressed on a number of solid and hematologic tumors, as well as many normal tissues. CytomX is evaluating CX-2029 in a Phase 1/2 clinical trial as monotherapy. CD71 is an excellent “internalizer,” which has the potential to efficiently deliver toxin to tumor cells. ...
Manufactured by:Catalent, Inc based inSomerset, NEW JERSEY (USA)
Antibody-drug conjugates (ADCs) combine the targeted binding specificity and pharmacological advantages of monoclonal antibodies with the potency advantages of small molecule chemotherapy agents via conjugation with chemical linkers. With 10 approved products and a large and growing list of programs in clinical and pre-clinical development, ADCs ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Doxorubicin hydrochloride (Hydroxydaunorubicin hydrochloride), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride inhibits topoisomerase IIwith an IC50 of 2.67 μM, thus stopping DNA replication. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces ...
Premium
Manufactured by:AB Sciex LLC based inFramingham, MASSACHUSETTS (USA)
Biotransformation studies are necessary for both small and large molecule therapeutics. From fast and efficient metabolic stability and soft spot analysis to in-depth, comprehensive identification of metabolites and catabolites in a sample, SCIEX offers an integrated solution to give you confident answers ...
Manufactured by:Epitope Diagnostics, Inc. (EDI) based inSan Diego, CALIFORNIA (USA)
This anti-MMAE monoclonal antibody is designed for use in an ELISA environment. It is the primary antibody used in the Epitope Diagnostics Intact MMAE Antibody-Drug Conjugate ELISA Kit. ...
Manufactured by:Epitope Diagnostics, Inc. (EDI) based inSan Diego, CALIFORNIA (USA)
This anti-MMAF monoclonal antibody is designed for use in an ELISA environment. It is the primary antibody used in the Epitope Diagnostics Intact MMAF Antibody-Drug Conjugate ELISA Kit. ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab is used for the synthesis of antibody-drug conjugates (ADC) drugs. Antibody-drug conjugates with sacituzumab (sacituzumab ...
Manufactured by:Context Therapeutics Inc. based inPhiladelphia, PENNSYLVANIA (USA)
There is growing interest in applying antibody modalities including bispecifics, antibody-drug conjugates, and CART to solid tumors. However, identifying appropriate tumor-specific targets that avoid adverse effects in healthy tissue has been challenging. The tight junction protein Claudin 6 (CLDN6) is a validated therapeutic target for many solid tumor types, ...
by:Zymeworks Inc based inVancouver, BRITISH COLUMBIA (CANADA)
with a modular suite of proprietary cytotoxins (cell-killing compounds), stable linkers, and conjugation technologies. A broader window of opportunity. Deliver potent cell-killing compounds specifically to diseased target cells with optimal safety and efficacy. ZymeLink™, a next-generation antibody drug conjugate (ADC) platform, is a suite ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and ...